This post by MDV brings to my mind two mind boggling CD12
This post by MDV brings to my mind two mind boggling CD12 scenarios.
First, MDV offers the possibility that mortality is leronlimab dose-respondent.
Second, it occurs to me that RO could prove dose dependent life saving capability of LL, but Cytodyn doesn't have the data either because it was not done on all CD12 patients or because what RO data was collected is not in Cytodyn's possesion and is thus not presentable to the FDA.
"What I can say is in the first 100 patients there was quite a difference in RO between the two cohorts, survival data of course is forthcoming. Occupancy can vary amongst treated patient, but if those with the highest occupancy survive it could lead to fast track."
The first mind-boggling concept that MDV offers is the following:
What if the only CD12 patients who died were patients who had some "low" level of RO.
Maybe every patient who survived has RO greater than 90% at day seven, for example.
That is a p-value of of at least as good as .001.
This situation seems potentially possible to me as the dose of leronlimab was just grabbed from HIV.
Somewhat hilariously, the only way to set the dose for covid was to use the Patterson CCR5 RO data that was just rejected by the FDA for HIV!?!?!?!?!?!?
There have never been any dose limiting LL toxicities observed in humans.
Maybe covid just needs a higher dose than HIV.
We already have a very strong hypothesis that the dose method for covid is wrong and should be intravenous instead of subcutaneous.
Covid is an emergency condition. HIV is chronic.
Maybe the covid dose was not high enough and that's why the covid LL patients died. CD12 RO tests could indicate that if some LL CD12 patients had been given a higher LL dose, then all of the covid LL patients would have survived.
Well, even if that possibility doesn't make your head spin, then the second possibility could still make your head explode.
What if Cytodyn does not have the RO data that demonstrates that LL covid survival is dose dependent?
What if the reason is because CD12 RO was not done because of the split with Patterson?
What if some data is done, but Cytodyn doesn't have it because of their spat with Patterson?
3
1
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Bringing New Leadership to Charter Next Generation It's an intriguing time to be watching Charter Next Generation (CNG) as they just added a heavyweight to their executive team. Todd Herndon, a veteran with more than three decades of financial savvy, steps in as their new Chief Financial Officer. This is like a football team drafting a star quarterback right before the...
Continue Reading
Pioneering Leadership for Children's Brain Tumor Network In a world where every advance in pediatric oncology can make a measurable difference, the Children's Brain Tumor Network (CBTN) has just unveiled quite the ace up its sleeve: Dr. Sarah Leary. She's stepping in as Co-Chair of its Executive Board, taking the reins alongside Brian Rood, MD. With extensive experience...
Continue Reading
iFranchise's Unyielding Dominance in Franchise Consulting Five seconds in the franchise game, and you'd know that staying on top is a grind. But when you're iFranchise Group, it seems like the eighth time is the charm—if there ever was a need for luck. These folks have secured the number one spot in Entrepreneur magazine's Top Franchise Suppliers ranking yet again....
Continue Reading
A New Twist on Protein Beverages Today, Matchi Global LLC is rolling out something new and bold: canned protein matcha lattes. It's not just another protein shake disguised in green robes. Oh no, this is a straight-up attempt to mesh pure ceremonial-grade matcha with a full 20 grams of complete filtered milk protein. And they’re delivering it all without any of those...
Continue Reading
A Fresh Chapter for Half Moon Cay Mark it down, folks—Holland America Line is shaking things up over at RelaxAway, Half Moon Cay. The cruise line, known for its deep roots in premium cruising, is pouring resources into its private island playground to celebrate its 30th anniversary in 2027. And the timing couldn't be more calculated, what with peak cruise season around...
Continue Reading
Shaking Up the Job Market with AI Skills What's shaking things up this time around? Handshake's dramatic unveiling of its AI Skills Studio, that's what. While the world spins on its financial axis, Handshake's showing up with a toolkit that's not just geeky gobbledygook. They're dead set on prepping job seekers with the nitty-gritty of AI know-how hosted in a rather...
Continue Reading
Pharmacy Certification Made Easy When ScriptSafe rolled out its certification service for pharmacies, it felt like the industry's straitjacket was finally coming off. We’re talking about a process that traditionally took months, cost a small fortune, and made pharmacies fill out forms like they were honing a doctoral thesis. But now, you've got ScriptSafe offering a...
Continue Reading
ViewScan's Latest Step in AI-Powered Monitoring Long Island's own ViewScan just kicked up some dust in the AI-based monitoring scene. This outfit is rolling out a new release of its ViewScan Protect software, fortified with advanced analytics aimed at beefing up security and operational efficiency. Now, before you gloss over this news as just another tech update, let me...
Continue Reading
A Fresh Start for Young Careers with CareerPath You remember the time in life when we thought just having a degree meant something? Well, the game’s changed, and now it’s a twisted jungle where young folks struggle to find their footing. Partners International, a name I’m no stranger to—known for their human capital wizardry—seems to have noticed this chaotic...
Continue Reading
Changing the AI Game in Enterprise At the heart of Tel Aviv-Yafo, ABnet Communication Ltd. is spitting fire, and this ain't your average tech chatter. They're drilling right down to the marrow, stressing just how much Anthropic—kingpin of advanced AI for enterprises—is shaking up the corporate shell game. Today’s conversation leans heavily into autonomous AI, and...
Continue Reading
Top 5 Most Recently Viewed Articles
Exciting Clinical Developments at Regulus Therapeutics Regulus Therapeutics Inc. (NASDAQ: RGLS), a pioneering biopharmaceutical company, recently unveiled some thrilling updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) program for its investigational drug, farabursen (RGLS8429). This announcement signals substantial advancements in the clinical...
Continue Reading
Understanding the Global Smart Parking Market Surge The global smart parking market is undergoing an extraordinary transformation, projected to reach a staggering $48.3 billion in the coming decade. Currently valued at around $8.5 billion, this significant leap is driven by an impressive compound annual growth rate (CAGR) of 19.3%. Such growth indicates not only...
Continue Reading
Perrigo's Ambitious Plans for Future Growth Perrigo Company plc (NASDAQ: PRGO) has set its sights on substantial growth over the next few years, aiming to boost sales and enhance its operating margins by 2027. Following a recent investor day, the company clarified its financial targets for 2025, igniting optimism among investors and industry observers alike. Sales...
Continue Reading
Understanding the Growth and Performance of Trifork Group The Trifork Group has demonstrated remarkable resilience through changing economic landscapes in 2024, reporting a net profit of EURm 17.9 and an impressive earnings per share growth of 13.3%. The company's adaptability amidst market challenges speaks volumes about its operational prowess and strategic planning....
Continue Reading
Unveiling Form: Transforming the SocialFi Landscape Form has recently emerged from stealth mode, establishing itself as a pioneering force within the SocialFi space on Ethereum. This innovative platform, affiliated with Roll Labs, has launched its native yield campaign along with a pre-deposit initiative, setting the stage for widespread adoption. What is SocialFi and Why...
Continue Reading